20
https://pubmed.ncbi.nlm.nih.gov/38112340
The EfficAPSI cohort, created by linking a sublingual immunotherapy registry and a French healthcare insurance database, includes a large number of person-years of follow-up and will allow for rigorous evaluation of the effectiveness of personalized liquid allergen immunotherapy in real-life.
